Elpiscience

Elpiscience is a global clinical-stage biopharmaceutical company focused on cancer immunotherapy. Elpiscience is committed to leading the innovative development of next-generation cancer immunotherapy. The company's pipeline covers a wide range of targets, with several innovative products currently under research and development. A key focus is converting "cold" tumors into "hot" tumors, with the aim of developing more effective next-generation cancer immunotherapies. Currently, ES104, ES101, ES102, and ES002 have all been approved to enter clinical trial stages. Elpiscience’s sustainable pipeline forms a solid foundation for the development of more effective next-generation cancer immunotherapies. Elpiscience is led by seasoned professionals in the biopharmaceutical industry and backed by prestigious international and domestic top-tier investors, including Lilly Asia Ventures, Hillhouse Capital, HD Investment, Greater Bay Area Homeland Development Fund, CDH Investments, Cormorant Asset Management, and Superstring Capital.